알림
뒤로

연사소개



○ 경력


2017 - 현재

CEO, PhAST Corp., Boston MA, USA

2015 - 2017Research Affiliate, MIT, Cambridge MA, USA
2009 - 2010Researcher, Institute of Advanced Machinery and Design, Seoul, Korea
2007 - 2009Engineer, Hyundai Motor Company (HMC), Namyang, Korea


[세션 2-1 연사]

손 광 민

PhAST Corp. CEO

초록  

○ PhAST – the future of rapid infectious diseases testing powered by AI/ML

  • Introduction of PhAST: PhAST is an AI healthcare technology company developing computer vision technology to help tackle the global healthcare threat of antibiotic resistance. The company is headquartered in Cambridge, MA, with offices in Zurich, and Seoul, South Korea. PhAST collaborates with leading healthcare institutions, such as Brigham and Women’s Hospital, the Infectious Disease Institute at the Harvard Medical School, and Seoul National University Hospital for clinical and product validations.
  • AI/ML platform overview: Pathogen phenotypes (= features) are measured at the single-cell level through advanced computer vision, image analysis and cloud computing, augmented by artificial intelligence and machine learning (AI/ML).
  • The Future of Healthcare AI & Big Data: By leveraging patient sample images, laboratory information system (LIS) and electrical healthcare record (EHR) data, PhAST’s AI/ML platform provides clinical decision support for doctors, workflow improvement for hospitals, and helps accelerate the drug development process for pharmaceutical companies.pharmaceutical companies.pharmaceutical companies.pharmaceutical companies.pharmaceutical companies.


연사정보

[세션 2-1 연사]

손 광 민

PhAST Corp. CEO

○ 경력


2017-현재
CEO, PhAST Corp., Boston MA, USA
2015-2017
Research Affiliate, MIT, Cambridge MA, USA
2009-2010Researcher, Institute of Advanced Machinery and Design, Seoul, Korea
2007-2009
Engineer, Hyundai Motor Company (HMC), Namyang, Korea

초록  


○ PhAST – the future of rapid infectious diseases testing powered by AI/ML

ㆍIntroduction of PhAST
: PhAST is an AI healthcare technology company developing computer vision technology to help tackle the global healthcare threat of antibiotic resistance. The company is headquartered in Cambridge, MA, with offices in Zurich, Switzerland, and Seoul, South Korea. PhAST collaborates with leading healthcare institutions, such as Brigham and Women’s Hospital, the Infectious Disease Institute at the Harvard Medical School, and Seoul National University Hospital for clinical and product validations.

ㆍAI/ML platform overview
: Pathogen phenotypes (= features) are measured at the single-cell level through advanced computer vision, image analysis and cloud computing, augmented by artificial intelligence and machine learning (AI/ML).

ㆍThe Future of Healthcare AI & Big Data
: By leveraging patient sample images, laboratory information system (LIS) and electrical healthcare record (EHR) data, PhAST’s AI/ML platform provides clinical decision support for doctors, workflow improvement for hospitals, and helps accelerate the drug development process for pharmaceutical companies.